Industry in brief | Recordati, Genomma, Daiichi Sankyo
2 August 2019
Recordati, Genomma Lab and Daiichi Sankyo have recently released financial results.
Industry News - Tag: Recordati
You can read Premium News stories in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
Recordati sets out its plans for OTC business
Premium
16 May 2019
Italian pharmaceutical company Recordati is seeking further OTC acquisitions, according to chief executive officer Andrea Recordati.
Recordati confirmed as chief executive officer
12 February 2019
Recordati reported worldwide sales up by 5.0% to EUR1.35 billion (USD1.52 billion) in 2018, and confirmed Andrea Recordati as chief executive officer following the recent change of ownership.
Italy's Recordati acquires France's Tonipharm
Premium
27 December 2018
Italian pharmaceutical company Recordati is acquiring French OTC firm Tonipharm, including its Ginkor brand, for an undisclosed sum.
Companies in brief | Boiron, Ipsen, Recordati
30 October 2018
Boiron, Ipsen and Recordati have just announced financial results.
Ipsen, Boiron, Daiichi-Sankyo, Recordati in brief
1 August 2018
Ipsen Consumer Healthcare, Boiron, Daiichi-Sankyo's OTC business and Recordati have just released financial results.
CVC to acquire majority stake in Recordati
2 July 2018
A consortium led by private-equity firm CVC Capital Partners is acquiring a majority stake in Italian pharmaceutical company Recordati for EUR3.03 billion (USD3.50 billion).
Recordati family confirms talks with CVC
Premium
25 June 2018
The Recordati family has confirmed that talks have been held with private-equity firm CVC Capital Partners about a sale of the family's controlling interest in Italian pharmaceutical company Recordati.
Recordati acquires Italian firm Natural Point
Premium
13 June 2018
Recordati has acquired Italian vitamins, minerals and supplements (VMS) specialist Natural Point for an undisclosed sum.
Recordati declines to comment on media reports
Premium
16 May 2018
Recordati said its OTC business had generated 16.4% of sales in the first quarter of 2018, but declined to comment on a Reuters report that it had recently held takeover talks with a private-equity firm.